MF2 HEMATOLOGY Flashcards

1
Q

Hematopoeisis

A

Monoblast -> monocyte
Myeloblast -> basophil,
Common -> neutrophil,
Myeloid eosinophil
Promegakaryocyte -> platelets
Preerythroblast -> RBCs
Stem cell ->

                 Common                                   B-lymphocyte
                 Lymphoid -> Lymphocyte ->  NK Cell
                                                                     T            -> Th & Tc

Basophil, neutrophil, eosinophil = 5-10 days
Platelets = 7-10 days
RBCs = 100-120 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Pancytopenia

A

BM SUPPRESSION
- Drugs sequestration
> Chemo
> Radiation
> HIV meds
> Anti-seizure
> Anti-thyroid
> Sulfonamides
- Infection
> Viral (HIV, Hep B, EPV, parvovirus B19)
> Bacterial (TB)
- Illness
> MDS
> Lupus
> DIC
> Starvation, Anorexia nervosa
> Autoimmune destruction
> Aplastic anemia (acquired, inherited)
- Fanconi
> Sarcoidosis

SPLENOMEGALY

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Microcytic Anemias

A

TAILS (thalassemia, anemia chronic disease, Fe, lead, sideroblast)

DECREASED HEME DECREASED GLOBIN

  • Fe deficiency
    > Sometimes high platelets
  • Sideroblastic
    > High hepcidin, lead
    > Buildup Fe RBC in periphery
    > Defect ih heme synthesis
  • Copper deficiency
  • Anemia chronic disease
    > Hepcidin (liver) response to inflammation
    > Feroportin in macros

DECREASED GLOBIN
- Thalassemia
> alpha
- Minima: silent
- Minor: trans v cis
- HbH: moderate, 4B
- Hb Barts: deadly

> beta
- Minor: often silent
- Intermedia: less B
- Major: no B; 3-6 months; anemia, jaundice, hemochromatosis, large forehead, cheekbones

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Normocytic Anemia

A

—- HEMOLYTIC —-

INTRINSIC
- Membrane Issue
> Hereditary spherocytosis (no ankyrin or spectrin)
> Eliptocytosis
> Paroxysmal nocturnal hemoglobinuria (complement
mediated)
- Enzyme issue
> G6DPH anemia (ROS destroy Hb -> Heinz bodies;
common in young African Americans, post infection)
- Folic acid
> Pyruvate kinase deficiency (less ATP –> rigid)
- Hemoglobin Issue
> Sickle cell anemia (B globin point mutation; shape
change when deoxy -> aggregate -> polymers -> lyse->
free Hb -> low haptoglobin -> high unconjugated
bilirubin (jaundice, gallstones) -> increased BM to
compensate & extramedullary hematopoeisis
(hepatomegally) -> VASO-OCCLUSION -> acute chest,
stroke (Moya-Moya), pain crisis, auto-splenectomy,
renal necrosis, priapism, aplastic crisis, marrow infarct
(-> fat emboli);
**Howel-Jolly bodies
**Folic acid, hydroxyurea, supportive care for vaco-occ
> Hemoglobin C disease

EXTRINSIC
- Infection (fever, rash)
> Sepsis
> Malaria
> Babesiosis
> Disseminated C. difficile
- Autoimmune
> Cold ( - IgG, + IgM )
> Warm ( + IgG )
- Microangiopathic hemolytic anemia (MAHA)
> DIC (septic, high coagulation, low fibrinogen)
> TTP (fever, anemia, thrombocytopenia, renal, neuro)
> HUS (younger, prior GI infection, acute renal failure)
> HELLP (pregnant, elevated LFTs; preeclampsia)
> Mechanical valve (chew up RBCs)

—-NON-HEMOLYTIC —-
- Hypothyroidism
- Early Fe deficiency
- Liver failure
- Early B12/Folate deficiency
- Poor gut absorption (low Fe and B12)
- CKD (kidneys make EPO)
- Hemorrhagic (acute blood loss)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Macrocytic Anemia

A

MEGALOBLASTIC (DNA synthesis issue)
- B12/Folate deficiency (pancytopenia)
- Fanconi aplastic anemia (pancytopenia)
- Orotic aciduria

NON-MEGALOBLASTIC
- Liver disease
- Diamond Blackfam anemia
- Alcohol abuse

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Ferritin vs transferrin

A

Ferritin: Fe storage
> Fe deficiency anemia low
> Anemia chronic disease high

Transferrin: Fe binding
> Fe deficiency anemia high
> Anemia chronic disease low

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Hemostasis: regulation

A
  • Secrete NO, PGI2 –| platelets
  • Heparin sulfate binds antithrombin III –| II, IX, X
  • Thrombomodulin binds II –> protein C –| V, VIII
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Hemostasis Steps

A
  1. Vascular spasm: endothilin, inflammation -> smooth muscle contraction
  2. Platelet plug formation: vMF by endothelial cells –> platelets bind via GpIa –> bind eachother by GpIIb/IIIa & fibrinogen –> secrete ADP, thromboxane A2, serotonin –> stimulate platelets & vasocontriction

***Aspirin inhibits TXA2

  1. Coagulation:
    > Extrinsic: III –> VII –> IX
    > Intrinsic: XII –> XI –> IX
    > Common: Ix + VIII –> X + V –> prothrombin activator
    –> II + I –> Fibrin + XIII –> FIBRIN MESH

**Not made by liver: III, VIII
**Shortest half-life: VII
**Longest half-life: II
**Made with vitamin K: X, IX, VII, II (1972)
> Warfarin inhibits VK

  1. Clot retraction: platelet-derived growth factor (collagen, endo repair)
  2. Fibrinolysis: plasminogen eats clot
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Coagulation Tests

A
  • INR: problem with extrinsic and/or common pathway
    (ratio measures time to clot)
  • aPTT: problem with intrinsic and/or common pathway
    (activation partial thromboplastin time)
  • TCT: activity of fibrinogen (I; thrombin clotting time)
  • Factor deficiency vs inhibitor: mix with normal blood
    > Corrects: deficiency
    > Does not correct: inhibitor (auto-Ab; if delayed often
    for VII, VIII b/c delayed activation)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Primary hemostasis vs secondary hemostasis bleeding disorders

A

PRIMARY
- Instant onset bleeding
- Mucosal bleeding (superficial)
> Nose
> Gums
> Periods
> GI
- Petichae (won’t disappear when you press)
- Vascular or Platelet issue

SECONDARY
- Delayed onset bleeding
- Joint bleeding
- Bleed into muscle -> compartment syndrome (*electrolytes, myoglobin, lactic acid, hyperK)
- Affecting intrinsic, extrinsic, or common pathway

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Bleeding disorders

A

PRIMARY

  • Vascular
    > Amyloidosis
    > HHT/Osler Webber Rendu (bad vessels)
    > Ehlers Danlos (bad collagen)
    > Scurvy (low vitC → bad collagen)
    > Cushings (thin walls)
    > Vasculitis, infection
  • Platelets
    > Quantitiative
    - Low production: aplastic anemia
    - Increased destruction: ITP, TTP/HUS, HIT
    - Sequestration: splenomegaly
    > Qualitative
    - Bernard soulier syndrome (Gp1b deficiency)
    - Glanzmans syndrome (GpIIb/IIIa)
    - Drugs (ASA, EtOH, NSAIDs)
    - Renal failure
    - Myeloproliferative disorder
    > vWD: most common inherited bleeding disorder
    - VIII broken down faster, eventual deficiency
    - Type 1: 3/4 cases; mild quantitative defect, non-severe
    - Type 2: qualitative, moderate-severe
    > A = reduced platelet adhesion b/c multimer
    > B = increased GPIb affinity (**don’t use DDAVP)
    > M = reduced platelet adhesion
    > N = decreased FVIII affinity (recessive)
    - Type 3: quantitative, near/total absence, severe (rec)
    - Epistaxis, oral cavity bleeding, menorrhagia
    - Normal PT, n/low platelet, n/prolonged aPTT, vWD
    testing, VIII activity
    - TREATMENT: estrogen contraceptives for
    mennhoragia, DDAVP for mild (1, 2A); if
    active bleeding, surgery desmopressin
    (DDAVP), vWF:VIII, antifibrinolytics
    (tranexamic acid)

SECONDARY
- Intrinsic
> Hemophilia: X-linked recessive, 50% severe
- Easy bruising, hemarthrosis, epistaxis, hematomas
- Prolonged aPTT, PT/INR, vWF:Ag, platelets normal
- Hemophilia A: VIII deficiency, most common
- Hemophilia B: factor IX deficiency, “Christmas”
- TREATMENT: desmopressin (DDAVP), VIII concentrate,
antifinrinolytics (tranexamic acid)
> vWD
> Factor IX deficiency: common in Ashkenazi Jewish, mild

  • Extrinsic
    > Factor VII (acquired factor inhibitor; malignancy,
    autoimmune disorders, post-partum)
  • Common
    > Vitamin K deficiency (needed for some factors; 1972)
    - Drugs: warfarin, antibiotics
    - Poor diet
    - Biliary obstruction
    > Liver disease (makes factors)
    - Thrombocytopenia, deficiency in factors (but VIII), less
    II, less anticoagulants and altered fibrinolysis
    > DIC (use up factors)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Thrombocytopenia

A

**mucocutaneous bleeding, epistaxis, perioperative bleeding, heavy period, bruising, petichiae, ecchymoses, purpura (non-palpable, wet)

INCREASED DESTRUCTION
- Immune
> ITP
> Viral: HIV
> Systemic: SLE, RA
> Alloimmune
> Drug-induced
- HIT
- Quinine
- Sulfonamides, ampicillin, vancomycin
- Acetaminophen, ibuprofen, naproxen (aleve)
- Non-immune
> HELLP, preeclampsia
> Thrombotic microangiopathies: hemolytic anemia, low
platelets, organ damage from microthrombi
- TTP
- HUS
> DIC

DECREASED PRODUCTION
- B12/Folate deficiency
- Marrow damage
> Chemo, radiation
> Aplastic anemia
> Malignancy
> Myelodysplastic
> Drug-induced
- Valproic acid
- Daptomycin
- Linezolid
> Congenital
- Alport (kidney disease, TPO)
- Fanconi syndrome (kidney disease, TPO)

SEQUESTRATION
- Splenomegaly
> Liver failure
> Portal HTN
> Infection (HIV, mono, Hep C, Tb, endocarditis)
> Amyloidosis, sarcoidosis, hemochromatosis
- Malignancy
> Lymphoma
> Leukemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

HIT

A

Heparin-induced thrombocytopenia (HIT)

  • Type I HIT: also known as heparin-associated thrombocytopenia (HAT), non-immune mediated reaction.
    > More common than type II
    > Mild reaction, not associated with complications,
    platelet counts spontaneously normalize (even if
    heparin continued)
  • Type II HIT: immune, antibody-mediated reaction (PF4-heparin + IgG –> activates more platelets)
    > Time for Abs, 5 to 14 days after heparin
    > If exposed to heparin w/in 100 days, Abc may remain
    > Serious rxn -> hypercoagulable state ->
    venous/arterial thrombosis –> DVT, PE, skin necrosis
    > Macros eat IgG coated platelets
  • 4T SCORE
    > Thrombocytopenia (30-50% drop)
    > Thrombosis (DVT, MI, gangrene, etc)
    > Timing (5-14 days)
    > Thrombocytopenia (other causes)
  • ELISA: antibodies test
  • SRA: confirm IgG
  • TREATMENT
    > Stop heparin
    > Anti-thrombins: argatroban
    > Anti-X: rivoroxaban (take with food!!), apixaban, edoxapan
    > If on warfarin, stop and five vitK
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

TTP

A

Thrombotic thrombocytopenic purpura (TTP)

  • Decreased ADAMTS-13 (cleaves vWF)
  • Congenital (5%) or acquired (95%; auto-Abs)
    > Congenital: kids
    > Acquired: adults; cancer, meds, HIV, BM transplant, SLE
  • PRESENTATION: Fever, Anemia, Thrombocytopenia, Renal failure, Neurological deficits ; can be mild and non-specific symptoms
  • INVESTIGATION: ADAMTS13 activity, inhibitor, platelets, hemolysis (cooms, haptoglobin, LDH), MCV, INR, creatining
  • TREATMENT: plasma exchange, corticosteroids, FFP, caplacizumab (prevents platelet vWF interaction, so stop thrombi formation)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Blood film interpretation (size, colour, shape)

A

SIZE
- Microcytic <80
- Normocytic 80-100
- Macrocytic >100
- Anisocytosis: variability in size
> low Fe, hemolytic, myelofibrosis, myelodysplastic

COLOUR
- Hypochromic: central pallor
> low Fe, anemia chronic disease, sideroblastic
- Polychromasia: increased reticulocytes (pinkish-blue)
> Increased RBC production by BM

SHAPE
- Poikilocytosis: increased proportion of abnormal shape
> Fe low, Hb-opathies, severe low B12, myelofibrosis

**myelofibrosis = bone marrow cancer (uncommon)
**myelodysplastic synromes = cancers where blood cells in the bone marrow do not mature

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

RBC inclusions

A
  • Nucleus: erythroblast → hemolytic anemia, BM infiltration
  • Heinz bodies: Thalassemia, G6PD, unstable Hb
  • Howell-Jolly bodies: megaloblastic, hyposplenism
  • Basophilic stippling: blue granulations → thalassemia, heavy
    metal, megaloblastic, myelodysplastic
  • Sideroblast: late erythrocyte → drugs, ethanol, hypothyroid,
    idiopathic
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Hypersegmented neutrophils

A

> 5 lobes suggests megaloblastic process
- B12 deficiency
- Folate deficiency

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Bone marrow aspiration and biopsy

A
  • Posterior iliac crest/spine, sternum (apsiration only)
  • Aspiration: takes fluid marrow for cell morphology
  • Biopsy: takes intact BM for histology and
    immunohistochemistry
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Causes of splenomegally

A

CHINA

Cirrhosis, congestion (portal HTN)
Hematological
> Nutritional anemias
> Hb-opathies
> Hemolysis
> Spherocytosis
> Sequestration crisis
Infectious
> Viral: EBV, HIV
> Bacterial: TB, endocarditis
> Parasitic: malaria, histoplasmosis, leishmaniasis
Neoplasm
> Leukemia
> Lymphoproliferative disease
Autoimmune
> SLE
> Sarcoidosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Microcytic anemia iron tests (ferritin, serum Fe, TIBC, % sat, RDW)

A

Ferritin Serum Fe TIBC % sat RDW
Fe deficiency: low low high low high
Chronic disease: n/high low low n n
Sideroblastic: n/high high n n/high high
Thalassemia: n/high n/high n n/high n/h

21
Q

Organs affected by vaso-occlusive crisis

A

Brain = ischemic or hemorrhagic stroke
Eye = hemorrhage, blindness
Liver = infarcts
Lung = acute chest syndrome, long-term pulmonary HTN
Gallbladder = stones
Heart = hyperdynamic flow murmurs
Spleen = enlarged (child), atrophied (adult)
Kidney = hematuria, proteinuria
Intestines = acute abdomen
Placenta = stillbirths
Penis = priapism
Digits = dactylitis
Bone = infarction, infection, avascular necrosis
Skin = leg ulcers (ankle)

22
Q

Drugs associated with thrombocytopenia

A

trimethoprim/sulfamethoxazole
heaprin
NSAIDs
Vancomycin
Digoxin (increased myocardial contractility, reduce HR)
Acetominaphen
Ethanol
H2-antagonists (for duodenal ulcers)

23
Q

Thrombocytopenia treatment

A

EMERGENCY
- Corticosteroids (prednisone)
- Antifibrinolytic if mucosal bleeding
- Platelet transfusion for major bleeding or urgent surgery

NON-URGENT
- 1st line: corticosteroids
- 2nd line: splenectomy, rituximab
- 3rd line: TPO receptor agonsist

24
Q

Affects of alcohol on hemostasis

A
  • Harm liver → TPO synthesis
  • Bone marrow suppression
  • Decrease lifespan of platelet
  • Directly toxic to platelets in blood
  • Impair platelet response to activators
  • Rebound effect: acute platelet drop when drinking then
    when stop → thrombocytosis → can lead to stroke
25
HUS (causes, clinical features, treatment)
Hemolytic Uremic Syndrome - Predominantly children and elderly - RBC lysis → kidney failure - Shiga toxin (E.coli) 90% - Clinical features > Severe thrombocytopenia > MAHA (non-immune hemolysis) /thrombotic microangiopathy > AKI > Bloody diarrhea > GI prodrome - Treatment > Supportive therapy: fluids, RBC transfusion, nutrition > Plasma exchange (some evidence)
26
DIC (causes, clinical features, treatment)
Disseminated Intravascular Coagulation - Excessive, dysregulated release of plasmin and thrombin → intravascular coagulation and depletion of platelets, coagulation factors, fibrinogen - Causes > Intravascular hemolysis: incompatible blood, malaria > Tissue injury: trauma, burns, crush injuries > Malignancy: solid tumors, hematologic malignancies > Snake venom (viper), fat embolism, heat stroke > Endothelial injury: infection, vasculitis > Liver disease > Splenectomy > Vascular stasis: hypotension, hypovolemia, PE, shock > Acute hypoxia/acidosis - Clinical features > Neuro: multifocal infarcts, delirium, coma, seizures > Skin: focal ischemia, gangrene, purpura fulminans > Renal: oliguria, azotemia, cortical necrosis > Pulmonary: ARDS > GI: acute ulceration, liver dysfunction > Adrenal: hemorrhage or infarct > RBC: microangiopathic hemolysis - Treatment > Underlying condition > Transfuse platelets if active bleeding > Fibrinogen concentrate if severe hypofibrinogenemia
27
Hypercoagulability Indications
- Patients with multiple recurrent thromboses - Warfarin-induced skin necrosis or neonatal purpura fulminanas (protein C or S deficiency) - Thrombosis at an unusual venous site - If abnormal blood work, constitutional symptoms, or physical exam suggestive of cancer → workup for malignancy
28
Pathophysiologic causes of hypercoagulability
ACTIVATED PROTEIN C RESISTANCE - Factor V Leiden - Most common cause of hereditary thrombophilia - Point mutationn in factor V → C cannot inactivate V PROTHROMBIN GENE MUTATION (PT) G20210A - Transposition of prothrombin promoter → increased prothrombin → increased thrombin PROTEIN C DEFICIENCY - C inactivates V and VIII using S as cofactor - Homozygous: neonatal purpura fulminans - Heterozygous: > Type I: decreased C levels > Type II: decreased C activity - Acquired: liver disease, sepsis, DIC, warfarin, some chemo PROTEIN C S DEFICIENCY - Type I: decreased free and total S - Type II: decreased S activity - Type III: decreased free S - Acquired: liver disease, DIC, pregnancy, nephrotic syndrome, infammatory conditions, warfarin ANTITHROMBIN DEFICIENCY - In absence of heparin, antithrombin inactivates thrombin, quickly with heparin - Causes: > Autosomal inheritance > Urinary losses in nephrotic syndrome > Reduced liver synthesis - May have heparin resistance ELEVATED FACTOR VIII LEVELS CONGENITAL DYSFIBRINOGENEMIA - May predispose to thromboembolic disease, bleeding, or both DISORDERS OF FIBRINOLYSOS - Includes congenital plasminogen deficiency, tissue plasminogen activator deficiency, association with VTE risk not clear
29
Venous Thromboembolism (definition, features, investigation)
- Thrombus formation and subsequent inflammatory response in superficial or deep vein > Superficial thrombophlebitis > DVT > PE **Most severe sequela of PE is chronic thromboembolic pulmonary HTN (CTEPH) - Clinical features > Unilateral leg edema, erythema, warmth, tenderness > Palpable cord (thrombosed vein) > Phlegmasia alba dolens (white appearance) and phlegmasia cerula dolens (acute pain and edema) with massive thrombosis > Homan's sign (pain or resistance with foot dorsiflexion); unreliable - Investigation > D-dimer test (rule out DVT; protein made when clot dissolves) > Doppler ultrasound > Venography (gold standard but expensive, invasive, higher risk) > CT pulmonary angiogram, V/Q scan
30
Virchow's Triad
- Endothelial damage > Exposes endothelium to prompt hemostasis > Decreased inhibition of coagulation and local fibrinolysis - Venous stasis > Immobilization inhibits clearance and dilution of factors > Post-MI, CHF, stroke, postoperative - Hypercoagulability > Inherited > Acquired > Age > Surgery (especially orthopaedic, thoracic, GI, GU) > Trauma (especially spine, pelvis, femur, tibia) > Neoplasms (especially pancreas, stomach, bladder, lymphoma, lung, testicular, colorectal, gynaecologic) > Blood dyscrasias, hyperviscosity (multiplemyeloma, polycythemia, leukemia, and SCD), hemolytic anemia > Prolonged immobilization (CHF, stroke, MI, leg injury) > Hormone (OCP, HRT, selective estrogen rec modulators) > Pregnancy > Heart failure
31
Venous thromboembolism treatment (initial, long-term, in hospital prophylaxis)
INITIAL TREATMENT - LMWH subcutaneous, lower bleeding risk > Predictable dose response > Lab monitoring not required > <1% HIT > Long term use associated with osteoporosis, $$ > Renally cleared (adjustment if renal dysfunction) - UFH if high risk of bleeds or surgery > Rapidly reversible by protamine > Must monitor aPPT or heparin levels to reach therapeutic level, higher risk of HIT - Direct thrombin inhibitors and Xa inhibitors as alternatives > II: Hirudin, lepirudin, argatroban, dabigatran > X: Apixaban, rivaroxaban LONG-TERM TREATMENT - Anticoagulation therapy > Warfarin: with heparin overlap for at least 48hr with INR>2, then discontinue heparin **LMWH more effective than warfarin at preventing recurrence of venous thrombosis in cancer patients > DOACs: - Apixaban or rivaroxaban (no lab monitoring) - Dabigatran (LMWH or IV heparin for 5d before) > If provoked VTE with transient risk factor: 3 months > If provoked VTE with ongoing risk factor: indefinite* > First unprovoked DVT/PE: >/= 3 months, indefinite* > Second unprovoked VTE: indefinite > Cancer-associated DVT: 3-6 months, longer if continued evidence of cancer *Annual reassessment - IVC filters > Temporary if acute DVT (<4wk) with contraindications to anticoagulant therapy (active bleeding, surgery) > Pro-thrombic in long term, so retrieve once safe - Special considerations > Pregnancy: LMWH during, then LMWH or warfarin 6wk post partum **avoid warfarin and DOAC in pregnancy, DOAC in breastfeeding > Surgery: - Preoperatively: IV heparin up to 4-6hr prior - Perioperatively: warfarin or DOACs discontinued at least 2-5 days prior - Postoperatively: IV heparin, MWH, DOAC - High risk: IV heparin or LMWH may be considered before & after while INR<2 IN HOSPITAL PROPHYLAXIS - Early ambulation, elastic compression stockings, intermittent pneumatic compression - LMWH - DOACs for orthopaedic surgery thromboprophylaxis
32
LMWH vs UFH
Low molecular weight heparin differs from unfractionated heparin: - The average molecular weight - It is more expensive - Greater effect on X, less on II - Only once or twice daily dosing (lasts longer) - The absence of monitoring the aPTT - The lower risk of bleeding, osteoporosis, and HIT
33
Pulmonary embolism treatment
- Admit for observation and stratify risk - Supplemental oxygen - Pain relief (narcotics, acetaminophen) - Acute anticoagulation > LMWH or > Rivaroxaban, apixaban, edoxaban or > Dabigatran - Long term anticoagulation > DOACs (rivaroxaban, dabigatran) > or warfarin **LMWH instead of warfarin if pregnant, cancer, high risk bleeding - IV thrombolytic therapy > If massive PE and no contraindications
34
What should be used in place of warfarin to prevent VTE in cancer patients
LMWH more effective than warfarin at preventing recurrence of venous thrombosis in cancer patients
35
What anticoagulants should be avoided in pregnancy? What instead?
Avoid warfarin and DOAC in pregnancy, DOAC in breastfeeding Use LMWH instead
36
Most common hereditary thrombophilia
Factor V Leiden (Activated protein C resistance) Resistance to activation of Factor V by activated protein C
37
Hemoglobins
HbA: 95-98% 2a2b HbA2b: 2-3% 2a2d HbF: fetal (higher O2 affinity for placenta) 0.8-2% 2a2g - 50-80% newborn
38
Lymphoma general presentations
GENERAL > Mediastinal mass > Splenomegaly > Fatigue > B symptoms (fever, night sweats, weight loss >10% in 6mo) HODGKINS LYMPHOMA > Contiguous spread, rarely extranodal > Reed-Sternberg cells (B-derived) > 50% connected to EBV > Better prognosis; often bimodal (20s then >50s) > Abnormal lymph nodes (enlarged, immobile, non-tender [unless fast growing], hard/rubbery) cervical > axilla > inguinal > Alcohol-induced pain > More likely classical NON- HODGKINS LYMPHOMA (90%) > Non-contiguous, often extranodal (GI, brain, skin), usually genetic mutation > HIV, EBV, HepB, HILV, autoimmunity risk factors > Spinal involvement (compression; decreased sensation) > CNS symptoms (focal neuro deficits) > GI symptoms (pain, bleeding, satiety, obstruction, nausea/vomit) > Recurrent infection, frequent bruising, fatigue (cytopenia) > 85% b cell
39
Hodgkin's Lymphoma (presentation, types)
CLASSICAL > More common > No CD45 or CD20, yes CD15 and CD30 > Nodular Sclerosis (most common; surround by collagen) > Lymphocyte-depleted (least common; lack reactive lymphos) > Lymphocyte-rich (best prognosis; mostly lymphos) > Mixed cellularity (2nd most common; neuts, eos, lymphos, plasma, histocytes surround)
40
Lymphoma diagnostic approach
1. Labs: > CBC (differential, blasts, peripheral smear, retic count) > HIV/Hep (risk factors) > Electrolytes > LDH (tumor lysis, cell death/turnover) > Uric Acid > Liver enzymes (liver involvement > Calcium (iodized or corrected for albumin; bone involvement) > Renal tests (before chemo) > PTT/PT (before biopsy) 2. Imaging > PET/CT (whole body) > CXR (mediastinal mass) 3. Biopsy > Excisional > Core needle > Bone marrow
41
Tumor Lysis Syndrome (cause, complications, treatment)
>Oncologic emergency triggered by tumor cell lysis >Seen most often in lymphomas/leukemias (rare solid tumors) >Caused by treatment or spontaneous (fast-growing) >K release: hyperkalemia (**arrhythmias, muscle weak) SOLUTION: insulin (&glucose), ventilin, K oxalate or diuretics (remove), calcium gluconate (stabilize heart) >PO4 release: hypocalcemia due to sequestration (**tetany, ECG changes, seizures) >Nucleic acid breakdown: hyperuricemia (**AKI) .........>Crystals: precipitate in tubules, minimal change; intrinsic .........>Stones: uric acid, calcium phosphate; post-renal >Rasburicase: chemotoxicity amelioration; recombinant uricase that breaks down uric acid .........>Side effects: anaphylaxis, methemoglobinemia (G6DPH low) >Allopurinol: prevents production, renally dosed .........>Side effects: dress syndrome (rare, more common in Asian) > Aggressive hydration, dialysis (for kidneys [crystals], for hyperK)
42
Non-Hodgkins Lymphoma (presentation, types)
B-CELL (85%) > Usually CD20 > Indulent (slow), aggressive, highly aggressive > Follicular: most common indulent; death prevention > Diffuse large B cell: aggressive; most common in adults > Mantle cell lymphoma: aggressive; more growth > Marginal zone lymphoma: indulent; most common type is MALT > Burkit lymphoma: highly aggressive; more division T-CELL > Adult T-cell lymphoma: HTLV (Japan, Carribbean) > Mycosis Furigosis: patches look like fungal infection, erythrodema
43
Lymphoma treatment approach
Rituximab: chimeric monoclonal Ab targets CD20 - Cyclophosphamide: alkylating agent (damage DNA; cycle indep) Hydroxy doxorubicin (adriamycin): anthracycline (cell cycle independent alkylating agent) Oncovin (vincristine): vinca alkaloid (inhibit microtubules; cycle-dependent) Prednisone: immunosupressant, feel better Radiation
44
Leukemia classification
- By how immature the originative cell is: >Acute: grow fast, acute onset; origin cells most immature >Chronic: grow fast, chronic onset; origin cell more developed - By cell type >Acute lymphocytic leukemia (ALL) --> B cell (more common) --> T cell >Acute myeloid leukemias (AML) --> Megakaryoblastic --> Myeloblastic --> Monoblastic --> Erythroblastic >Chronic lymphoid leukemia (CLL) --> B cell
45
Acute lymphocytic leukemia (ALL): Dx, Sx, prognosis
- Most common in kids, associated with Down Syndrome - INVESTIGATIONS: >CBC (small blasts, low RBCs & platelets) >peripheral blood smear (blasts, glycogen granules, fewer nuclei), flow cytometry (CD markers) >BM biopsy (to confirm diagnosis; Tdt protein) >Lumbar puncture (additional test to see spread to CSF) >HIV/Hep B screens (prior to treatment) - PRESENTATION: >Pancytopenia (increased infection, fatigue, bruising) >Bone pain (sternal pain common) >B Symptoms >Hepatosplenomegally >Lymphadenopathy >T CELL: thymus mass (can compress airway/esophagus), teenagers >B CELL: translocations (t12;21 kids, t9;22 adults), better prognosis in kids - PROGNOSIS: >60-70% 5 year survival adults >80% 5 year survival kids
46
Acute myeloid leukemias (AML)
- Most common leukemia among older adults (80%), median 65 years old - Most common risk factor is myelodysplastic syndrome, Down Syndrome, male - Environmental risk factors: benzene, radiation, chemo drugs - INVETIGATIONS: >CBC (big blasts, auer rods, more nuclei)** >Peripheral blood smear, flow cytometry (CD markers) >BM biopsy (to confirm diagnosis; Tdt protein) >Lumbar puncture (additional test to see spread to CSF) >HIV/Hep B screens (prior to treatment) - PRESENTATION: >Pancytopenia (increased infection, fatigue, bruising) >Bone pain (sternal pain common) >B Symptoms (fever less likely**) >Hepatosplenomegaly >Lymphadenopathy >Swollen gums** >DIC** >Tumor lysis syndrome** - PROGNOSIS >Worse than ALL; variable if respond to chemo ** = different from ALL
47
Chemotherapy Drug classes
1. Alkylating agents: unstable alkyl groups inhibit rep/trans > Cyclophosphamide > Platinum containing compounds **Myelosuppression, mucositis, nausea/vomiting, neurotoxicity, alopecia 2. Antimetabolites: immitate DNA ingredients >Cytidine analogs >Folate antagonists (methotrexate) >Purine analogs >Pyrimidine analogs 3. Antimicrotubular: target cytoskeleton (M phase) >Taxanes: disrupts eq of po/depol of microtubules >Vinca alkyloids: inhibit formation (vincristine) 4. Topoisomerase inhibitors: inhibit unwinding >Topoisomerase I inhibitors: prevent relegation >Topoisomerase II inhibitors: inhibit DNA synthesis/repair 5. Antibiotics: inhibit RNA/DNA synthesis >Release ROS, inhibit topoisomerase, intercalating agents >Actinomycin D >Doxorubicin (anthracycline) 6. Protein kinase inhibitors >Tyrosine kinase inhibitors (ex. t9;22 = BCR-ABL mutation) 7. Antibodies + Immunotherapy (more targeted) > Antibodies: Rituximab (CD20) > Immunotherapy: CAR-T cell therapy, checkpoint inhibitors 8. Miscellaneous: >Hydroxyurea >Tretinoin >Arsenic trioxide >Proteasome inhibitors
48
Febril Neutropenia
- Fever + neutrophil count (ANC) less than 1500cells/mL - Most common serious and common complication of cancer therapy - Infectious etiology usually unable to be determined (30%) - INVESTIGATION: > Complete blood count, 2 blood cultures, urinalysis, throat cultures - TREATMENT: >Low risk: oral fluoroquilolone + amoxicillin > High risk: IV antibiotics